Asset Details
Do you wish to reserve the book?
Fifty Years of JC Polyomavirus: A Brief Overview and Remaining Questions
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Fifty Years of JC Polyomavirus: A Brief Overview and Remaining Questions
Do you wish to request the book?
Fifty Years of JC Polyomavirus: A Brief Overview and Remaining Questions
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Fifty Years of JC Polyomavirus: A Brief Overview and Remaining Questions
2020
Overview
In the fifty years since the discovery of JC polyomavirus (JCPyV), the body of research representing our collective knowledge on this virus has grown substantially. As the causative agent of progressive multifocal leukoencephalopathy (PML), an often fatal central nervous system disease, JCPyV remains enigmatic in its ability to live a dual lifestyle. In most individuals, JCPyV reproduces benignly in renal tissues, but in a subset of immunocompromised individuals, JCPyV undergoes rearrangement and begins lytic infection of the central nervous system, subsequently becoming highly debilitating—and in many cases, deadly. Understanding the mechanisms allowing this process to occur is vital to the development of new and more effective diagnosis and treatment options for those at risk of developing PML. Here, we discuss the current state of affairs with regards to JCPyV and PML; first summarizing the history of PML as a disease and then discussing current treatment options and the viral biology of JCPyV as we understand it. We highlight the foundational research published in recent years on PML and JCPyV and attempt to outline which next steps are most necessary to reduce the disease burden of PML in populations at risk.
Publisher
MDPI AG,MDPI
Subject
Acquired immune deficiency syndrome
/ AIDS
/ Animals
/ Central nervous system diseases
/ Disease
/ Drugs
/ HIV
/ HIV/AIDS
/ Human immunodeficiency virus
/ Humans
/ immunocompromised population
/ Ligands
/ Patients
/ Polyomavirus Infections - diagnosis
/ Polyomavirus Infections - drug therapy
/ Polyomavirus Infections - history
/ Polyomavirus Infections - virology
/ Progressive multifocal leukoencephalopathy
/ Review
/ risk
/ Tumor Virus Infections - diagnosis
/ Tumor Virus Infections - drug therapy
/ Tumor Virus Infections - history
/ Tumor Virus Infections - virology
/ Viruses
